Eastgate Biotech Corp.
ETBI
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | |
|---|---|---|---|---|---|
| Revenue | 1,258.82% | 26.10% | -- | -- | -97.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,258.82% | 26.10% | -- | -- | -97.68% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 423.50% | 43.71% | -33.16% | -35.46% | -47.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 302.42% | 36.51% | -26.46% | -33.79% | -50.71% |
| Operating Income | -297.09% | -9.88% | 26.46% | 33.77% | 46.24% |
| Income Before Tax | -245.00% | -51.63% | 34.94% | 31.06% | 43.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -245.00% | -51.63% | 34.94% | 31.06% | 43.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -245.00% | -51.63% | 34.94% | 31.06% | 43.37% |
| EBIT | -297.09% | -9.88% | 26.46% | 33.77% | 46.24% |
| EBITDA | -304.00% | -- | -- | 34.37% | 47.12% |
| EPS Basic | 0.00% | 20.00% | 38.78% | 37.93% | 60.53% |
| Normalized Basic EPS | 10.00% | 20.00% | 29.63% | 33.33% | 58.33% |
| EPS Diluted | 0.00% | 20.00% | 38.78% | 37.93% | 60.53% |
| Normalized Diluted EPS | 10.00% | 20.00% | 29.63% | 33.33% | 58.33% |
| Average Basic Shares Outstanding | 262.99% | 87.48% | 6.63% | 8.87% | 40.94% |
| Average Diluted Shares Outstanding | 262.99% | 87.48% | 6.63% | 8.87% | 40.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |